Regional Therapies Utilized in Treating Unresectable Colorectal Adenocarcinoma with Peritoneal Metastases.

Shray Malik, Vanessa Le, Farshid Dayyani, Maheswari Senthil, Oliver S Eng, Michael P O'Leary

Abstract readReview

In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shray MalikDepartment of Surgery, University of California-Irvine, Orange, CA 92868, USA.ORCID 0000-0002-9165-2332

Vanessa LeDepartment of Surgery, University of California-Irvine, Orange, CA 92868, USA.

Farshid DayyaniDepartment of Medicine, Chao Family Comprehensive Cancer Center, University of California-Irvine, Orange, CA 92868, USA.ORCID 0000-0002-4970-5189

Maheswari SenthilDepartment of Surgery, University of California-Irvine, Orange, CA 92868, USA.

Oliver S EngDepartment of Surgery, University of California-Irvine, Orange, CA 92868, USA.

Michael P O'LearyDepartment of Surgery, University of California-Irvine, Orange, CA 92868, USA.ORCID 0000-0002-4756-4271

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal peritoneal metastases portend a poor prognosis when compared to other isolated sites of metastatic disease. The advent of regional therapies, including cytoreductive surgery, have improved outcomes for patients with peritoneal carcinomatosis. However, these options are typically only available in patients deemed to have resectable disease. For patients with unresectable peritoneal disease, non-surgical regional therapy has only been studied in early-phase clinical trials. This represents a gap in therapy in a population with a desperate need. In this review, we highlight the current limited data, as well as postulate on the future direction of regional therapies in patients with unresectable peritoneal metastases from colorectal adenocarcinoma.

Indexed as

colorectal peritoneal metastaseslocoregional therapyunresectable peritoneal carcinomatosis

Identifiers

PMID41827796

DOI10.3390/cancers18050863

PMCPMC12984780

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.